ArticleCancer communications (London, England)2024

SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study.

Shuqui Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.